Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by Goaweighon Aug 29, 2020 11:10am
254 Views
Post# 31475084

RE:Zacks

RE:ZacksIs that before or after the 10 for 1 roll back ?
The constant pressure on the stock may be because some anticipate a roll back is coming sooner than later. That's not all bad as long as it's executed properly and a US broker/ Marketing specialist has been retained to manage the stock properly through a US led financing or to make sure any stock coming out is well placed.
Take a look at Green Power ( GPV ) for a recent example of a deal that was well managed on it's way to Nasdaq. That was a 7 for 1 roll back. The stock was trading at less than .50 equivalent in July, converted to $ 3.50 and is now around $ 28.00, an 8 bagger !

Sona is another recent example, a bio, it didn't require a roll back to qualify for an uplisting and it only tripled but still not bad.

I'm waiting for a knee jerk negative reaction to a roll back announcement and inted to take full advantage if it occurs.












Amigo11 wrote: Zacks out with an updated timeline/valuation 12 months out for $3. Per share of ATE-not quite sure why 500,000 were offered at the close at 39 cents.One side ,either the Buyers or the Sellers,is going to be horribly wrong !


<< Previous
Bullboard Posts
Next >>